London-based investment firm Samfara has completed the acquisition of Chr. Olesen Synthesis, a Danish manufacturer of controlled-substance active pharmaceutical ingredients (APIs), in what the firm describes as its first investment. The deal, announced on 2 October 2026, puts a specialist plant near Copenhagen that makes ingredients for opioid-dependence and ADHD medicines under new ownership. This article looks at what the company actually makes, why that niche is hard to enter and what remains unknown about the Samfara Chr. Olesen Synthesis transaction.
Key Takeaways
- Samfara completed the purchase of Chr. Olesen Synthesis on 2 October 2026. Financial terms were not disclosed.
- The company makes APIs and advanced intermediates for controlled substances, including buprenorphine and lisdexamfetamine, at a cGMP-certified site in Hvidovre, near Copenhagen.
- It supplies pharmaceutical companies in Europe, North America and the Middle East, according to the announcement.
- The plant has been in commercial production since 2015. The announcement did not give headcount or capacity.
- Samfara says it plans to develop capabilities, deepen customer relationships and enter new markets organically and through acquisitions.
What Does Chr. Olesen Synthesis Make?
An API is the biologically active component of a medicine, and an advanced intermediate is a late-stage chemical building block used to make it. Chr. Olesen Synthesis specialises in both for controlled substances, which are drugs regulated because of their potential for misuse. Its named products are buprenorphine, used in the treatment of opioid use disorder, and lisdexamfetamine, used to treat attention deficit hyperactivity disorder (ADHD).
The site in Hvidovre is certified under current good manufacturing practice (cGMP), the quality standard that regulators expect for pharmaceutical production. Customers are pharmaceutical companies, whose names have not been disclosed.
Chr. Olesen Synthesis at a Glance
| Item | Detail |
|---|---|
| Company | Chr. Olesen Synthesis |
| Location | Hvidovre, near Copenhagen, Denmark |
| Products | APIs and advanced intermediates for controlled substances, including buprenorphine and lisdexamfetamine |
| Quality status | cGMP-certified; in commercial production since 2015 |
| Customers | Pharmaceutical companies in Europe, North America and the Middle East |
| Buyer | Samfara, London-based private equity firm (first investment) |
| Completed | 2 October 2026 |
| Financial terms | Not disclosed |
Why Is Controlled-Substance API Manufacturing a Niche?
Making these ingredients involves more than chemistry. Controlled substances fall under international drug control treaties overseen by the International Narcotics Control Board, and each country applies its own licensing, record-keeping and security rules. Producers generally need permits to make, store and ship them, and customers need confidence that supply will be uninterrupted. Companies with an established track record and the right licences are therefore hard for newcomers to replicate quickly. This is general context and is not specific to Chr. Olesen’s own licences, which the announcement does not list.
Regulators also inspect the plants. In Europe, quality oversight sits with national authorities such as the Danish Medicines Agency alongside the European Medicines Agency, while products supplied to the United States must meet the expectations of the US Food and Drug Administration. One report says the combination of US and European compliance requirements creates high switching costs for customers. That is the report’s assessment, and we have not verified how many of the company’s customers are supplied to US standards.
The Medicines Behind the Ingredients
Buprenorphine is a partial opioid agonist used in medication-assisted treatment of opioid use disorder. Lisdexamfetamine is a prodrug of dextroamphetamine, meaning it is converted in the body to the active drug, and is used for ADHD. Demand for both is tied to prescribing trends, regulatory limits and generic competition, which the announcement does not address. We cannot say how much of Chr. Olesen’s output goes to each product.
Who Is Samfara?
Samfara is described as a London-based private equity firm that focuses on majority buyouts of European life sciences companies in the lower mid-market. Chr. Olesen Synthesis is its first investment, and the firm is reported to be backed by European and North American institutional investors and family offices. Samfara partners Helena Malchione and James Cocker said the deal reflects a strategy of finding winning companies in complex niches and backing them with capital and strategic support.
Chief Executive Thomas Moestrup is investing alongside Samfara. Jean-Francois Hilaire, a former chief executive of Unither Pharmaceuticals, is joining as board chair. Seller Mads C. Olesen said the time was right for new owners to take the business forward.
What Is Not Yet Known
- The price, financing structure and any earn-out or milestone terms.
- Plant capacity, headcount and utilisation.
- Which licences and inspection histories apply to the site.
- Samfara’s plans for further acquisitions and the timetable for them.
Related Coverage
For more on pharmaceutical manufacturing, see our reports on the Vetter’s fill-and-finish capacity expansion, the boiler blast at TIL Healthcare’s Sri City plant and the DaltonTx antibody discovery platform.
Our Assessment
In our assessment, the deal is a classic specialty-manufacturing buyout: a profitable-looking niche with regulatory barriers, an incumbent management team that stays on and a new owner with capital to expand. The unanswered questions are commercial rather than scientific, namely how concentrated the customer base is and how dependent the business is on two products. Until more detail is disclosed, the sensible reading is that this is a platform investment, not a one-off purchase.
Frequently Asked Questions
What did Samfara acquire?
Chr. Olesen Synthesis, a Danish maker of controlled-substance APIs and advanced intermediates, including buprenorphine and lisdexamfetamine.
When was the deal completed?
On 2 October 2026, according to the announcement. The financial terms were not disclosed.
Where is the plant?
In Hvidovre, near Copenhagen, Denmark. It is cGMP-certified and has been in commercial production since 2015.
What are buprenorphine and lisdexamfetamine used for?
Buprenorphine is used to treat opioid use disorder, and lisdexamfetamine is used to treat ADHD.
What does Samfara plan to do next?
It says it will develop the company’s capabilities, expand customer relationships and pursue new markets, both organically and through acquisitions.
How we reported this: details come from the announcement of the completed acquisition on 2 October 2026 and related reports. Company-reported statements are labelled, and where sources differ on background we say so. Financial terms were not disclosed. Last updated 5 October 2026. This article is for information only and is not investment or medical advice.
